|
Funding Agency: National Institutes of Health Title: Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed) Application Deadline: October 26, 2022 This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available. Funding Agency: National Institutes of Health Title: Galvanizing Health Equity Through Novel and Diverse Educational Resources (GENDER) Research Education R25 (R25 Clinical Trial Not Allowed) Application Deadline: January 07, 2023 The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this ORWH R25 program is to support educational activities that complement and/or enhance the training of a diverse workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Curriculum or Methods Development. Specifically, this FOA will support the development of short courses, training modules, curricula, and other educational activities to enhance knowledge of sex and gender influences on health and disease among scientists, clinicians, and health professionals, and other stakeholders to accelerate the translation of that knowledge into practice. Funding Agency: National Institutes of Health Title: NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) Application Deadline: Multiple dates This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. Funding Agency: National Institutes of Health Title: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required) Application Deadline: July 12, 2023 The purpose of this Funding Opportunity Announcement (FOA) is to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease. To facilitate clinical trial start up, and leverage existing datasets, preference will be given to applications focusing on diseases that are under study by the Rare Disease Clinical Research Network (RDCRN), and that involve collaborations with RDCRN clinical investigators. Funding Agency: National Institutes of Health Title: Point-of-Care Technologies Research Network: Technology Research and Development Centers (TRDC) (U54 Clinical Trial Optional) Application Deadline: January 07, 2023 The purpose of this funding opportunity announcement is to solicit Technology Research and Development Center (TRDC) applications for the Point-of-Care Technologies Research Network (POCTRN). The POCTRN catalyzes innovation in medical technologies through a network model that enhances complementary strengths and builds multidisciplinary partnerships across scientific/technological, clinical, regulatory, and commercialization domains. Each TRDC will accelerate the development, validation, and deployment of point-of-care, home-based, and other innovative testing technologies in a specific area of health research. The POCTRN TRDCs will merge scientific and technological capabilities and expertise with clinical need and market demand to address unmet testing, monitoring, and treatment demands. This opportunity is open to all applicants, including the existing POCTRN grantees as well as new applicants. Funding Agency: National Institutes of Health Title: BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) Application Deadline: October 13, 2023 This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging. Funding Agency: National Institutes of Health Title: More Monitoring of Cognitive Change, Continued (M3C3) (U2C Clinical Trial Optional) Application Deadline: October 20, 2022 This Funding Opportunity Announcement (FOA) invites applications to expand the content, design, and implementation of research infrastructure funded under FOA RFA-AG-18-012 Mobile Monitoring of Cognitive Change (U2C), also known as the Mobile Toolbox (MTB) Project. The expansion aims to (1) add assessments on mobile devices of non-cognitive socioemotional psychological functions, health states, and contextual factors that may modify cognitive performance; and (2) enable widespread dissemination and support for use of the tools developed for monitoring of age, state, context, or health condition-related changes in cognitive and non-cognitive abilities on mobile devices. The expanded MTB efforts must include the development, or support for development, of applications on the two leading smartphone platforms, the Android and iOS platforms, and the validation of new tests and items to be used on the platforms by age groups ranging from 20 to 85. The goals of this expanded platform are to support data collection efforts from participants enrolled in the project awarded through this FOA, as well as other NIH-funded studies through fiscal year 2027, and to enable the widespread sharing of both the collected data and the test instruments.
|
